Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAPSTER: Neoadjuvant Pembrolizumab and SABR for Renal Cell Carcinoma
NCT05024318Phase 2Recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Feb 2022
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in clear cell renal cell carcinoma (ccRCC), sponsored by Peter MacCallum Cancer Centre. Started Feb 2022; status: recruiting.
02
Drugs
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT05024318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05024318.